Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates
01:45pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Penny Stocks To Buy: 5 To Watch Before Next Week
11:52am, Wednesday, 01'st Mar 2023
Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cidara to Present at ESMO Targeted Anticancer Therapies Congress
08:00am, Tuesday, 28'th Feb 2023
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat
Cidara Therapeutics: FDA Approval Dead Ahead
05:23am, Monday, 30'th Jan 2023
Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
12:00pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
FDA decision expected by PDUFA target action date of March 22, 2023
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
06:24pm, Friday, 20'th Jan 2023 Benzinga
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets.
Genius Group Limited (NYSE: GNS) shares jumpe
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
01:00pm, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target
Cidara Therapeutics Could Soar On Rezafungin Approval
08:13am, Wednesday, 16'th Nov 2022
Rezafungin has an FDA approval deadline of March 22, 2023. The stock has been neglected by investors.
Cidara Therapeutics to Present at the Stifel Healthcare Conference
01:00pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien
Cidara Therapeutics to Present at the Stifel Healthcare Conference
08:00am, Tuesday, 08'th Nov 2022
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
09:47pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for p
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
12:00pm, Monday, 17'th Oct 2022 GlobeNewswire Inc.
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
08:00am, Monday, 17'th Oct 2022
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
12:00pm, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
08:05pm, Tuesday, 20'th Sep 2022 GlobeNewswire Inc.
Assigned PDUFA target action date of March 22, 2023 Assigned PDUFA target action date of March 22, 2023
